07:04 EDT Phathom Pharmaceuticals (PHAT) sees FY25 revenue $170M-$175M, consensus $170.4M
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals’ EoE Study: A Potential Game-Changer?
- Phathom Pharmaceuticals’ Vonoprazan Pregnancy Study: A Market Game Changer?
- Phathom Pharmaceuticals Publishes Phase 3 Trial Results
- Phathom Pharmaceuticals Appoints New Chief Financial Officer
- Phathom appoints Sanjeev Narula as chief financial, business officer